Clinical trials: Girls
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan
Alopecia, Baldness
Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss.
- Trial name
- NCT01325350
- Testing
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Where
- 2 sites in United States, Germany
- Volunteers
- 306 people
- Sponsor
- Allergan
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded…
- Trial name
- NCT04195750
- Testing
- Belzutifan, Everolimus
- Where
- 172 sites in United States, Brazil and 21 more
- Volunteers
- 755 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Kidney Diseases, Acute Kidney Injury
Nova Max Creatinine and eGFR Meter System
To assess the performance of the Nova Max Creatinine and eGFR assay in the hands of CLIA-Waived Point-of-Care users in at least three (3) distinct Point-of-Care clinical settings on venous, and capillary blood and compare the…
- Trial name
- NCT05118074
- Testing
- Creatinine, eGFR
- Where
- 3 sites in United States
- Volunteers
- 360 people
- Sponsor
- Nova Biomedical
Acute Transplant Rejection in Patients Receiving Allogeneic Renal Transplant
Generic Mycophenolate Mofetil Safety Study for Prophylaxis in de Novo Renal Transplant Patients in Jordan
The purpose of this observational study was to assess the safety and efficacy of generic mycophenolate mofetil in de novo renal transplant patients in Jordan where no visits or intervention(s) additional to the daily practice…
- Trial name
- MyOra-PASS (NCT03517982)
- Testing
- Mycophenolate Mofetil
- Where
- Jordan
- Volunteers
- 12 people
- Sponsor
- Hikma Pharmaceuticals LLC
Overactive Bladder
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
This Phase 3 trial will investigate the efficacy, tolerability and safety of fesoterodine fumarate (SR) (fesoterodine; SPM 907) in adult male and female subjects with overactive bladder syndrome.
- Trial name
- NCT00138723
- Testing
- SPM 907
- Sponsor
- Pfizer
Renal Insufficiency, Healthy
Clinical Pharmacology of FYU-981 (Subjects With Renal Insufficiency)
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety after single oral administration of FYU-981 to subjects with renal insufficiency and with normal renal function.
- Trial name
- NCT02347046
- Testing
- FYU-981, (Oral single dosing)
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Fuji Yakuhin Co., Ltd.
Gestational Diabetes, Pregnancy Complications
OneinSeven Gestational Diabetes Genetic and Socioeconomic Risk Study
The objective of the Gestational Diabetes Genetic Socioeconomic Risk Study is to generate genome wide association study data (GWAS) to calculate polygenic risk scores (PRS) for the development of gestational diabetes in pregnant…
- Conditions
- Gestational Diabetes, Pregnancy Complications, Pregnancy Related, Genetic Predisposition
- Trial name
- NCT04789473
- Testing
- Polygenic Risk Score Generation
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Prenome
Chronic Kidney Disease, Chronic Renal Insufficiency
Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.
This trial is conducted in Europe. Objective(s): To evaluate the effect of human growth hormone on infants aged 1 to 2 years with chronic renal insufficiency (CRI) and growth retardation despite an adequate dietary intake.
- Trial name
- NCT00184769
- Testing
- somatropin
- Where
- 20 sites in Portugal, Spain
- Volunteers
- 16 people
- Sponsor
- Novo Nordisk A/S
Neuroblastoma, Ewing's Sarcoma
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
This study will be carried out in children with diagnosis of cancer with tumors known to express N-glycolylated gangliosides. The disease must be resistant to conventional therapy.
- Conditions
- Neuroblastoma, Ewing's Sarcoma, Wilm's Tumor, Retinoblastoma
- Trial name
- NCT01598454
- Testing
- racotumomab
- Where
- Argentina
- Volunteers
- 15 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Overactive Bladder
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)
The purpose of this study is to compare the safety and efficacy of solifenacin with oxybutynin immediate-release (IR) for the treatment of overactive bladder (OAB).
- Trial name
- VECTOR (NCT00431041)
- Testing
- solifenacin, oxybutynin immediate release
- Where
- 12 sites in Canada
- Volunteers
- 132 people
- Sponsor
- Astellas Pharma Inc
Female Stress Incontinence, Pelvic Organ Prolapse
Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices
To monitor post-market performance through evaluation of short and long-term performance via: Efficacy Safety Patient reported outcomes
- Trial name
- CAPTURE (NCT01673360)
- Testing
- Elevate PC, Mini Arc Pro, RetroArc
- Where
- 19 sites in United States, Canada and 6 more
- Volunteers
- 401 people
- Sponsor
- ASTORA Women's Health
Human Papillomavirus Infection
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
The study is to evaluate immune response induced by 9-valent HPV study vaccine is non-inferior to those induced by GARDASIL® 9 administrated with 3-dose schedule in female participants aged 20-26 years in China, if the immune…
- Trial name
- NCT05662020
- Testing
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9
- Where
- China
- Volunteers
- 2,750 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Endometriosis
TUC3PII-01_TU2670 Phase IIa Clinical Study
This Protocol for TU2670 is to investigate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of TU2670 in subjects with moderate to severe endometriosis-associated pain.
- Trial name
- NCT05138562
- Testing
- Active Comparator: TU2670 320mg, Active Comparator: TU2670 240mg, Active Comparator: TU2670 120mg
- Where
- 40 sites in Czechia, Italy and 3 more
- Volunteers
- 86 people
- Sponsor
- TiumBio Co., Ltd.
Metastatic Renal Cell Carcinoma (mRCC)
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
The study aims to assess clinical outcomes in mRCC patients treated with sunitinib in second-line following IO therapy in real world clinical practices.
- Trial name
- NCT04175262
- Testing
- sunitinib
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- Pfizer
Tendinosis, Tendinopathy
Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis
The primary purpose of this study is to assess the safety profile of RCT-01 injections as compared to placebo injections. This study will also measure the impact these injections will have on tendon structure and function and the…
- Trial name
- ReaCT (NCT02330146)
- Testing
- RCT-01
- Where
- Canada
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- RepliCel Life Sciences, Inc.
Relative Bioavailability
A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations
This is a phase 1, randomised, open-label, three-way, three-period, crossover relative bioavailability study to assess the single-dose pharmacokinetics of FOR-6219 in capsule and tablet formulations in postmenopausal women.
- Trial name
- NCT04686669
- Testing
- FOR-6219 capsule formulation, FOR-6219 tablet formulation
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Forendo Pharma Ltd
Hepatitis C
Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325
The purpose of this study is to assess the effect of DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of the oral contraceptive agent.
- Trial name
- NCT02103569
- Testing
- FDC of Daclatasvir, Asunaprevir and BMS-791325, FDC of Norethindrone and Ethinyl Estradiol, BMS-791325
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Bacterial Vaginosis
Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis
This is an open-label, single-armed, multi-center study to evaluate clinical performance, tolerability, and safety of Gedea Pessary in 24 adult women with confirmed bacterial vaginosis (BV) according to fulfillment of at least 3…
- Trial name
- NCT03762083
- Testing
- pHyph generation I
- Where
- 2 sites in Sweden
- Volunteers
- 24 people
- Sponsor
- Gedea Biotech AB
End Stage Renal Disease
24 Hour Use of the Wearable Artificial Kidney
This is a prospective, interventional study designed to provide preliminary data on the human use of the WAK. Up to 10 subjects currently receiving intermittent hemodialysis (HD) treatment three times per week for end-stage renal…
- Trial name
- WAK US 1 (NCT02280005)
- Testing
- WAK Treatment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Blood Purification Technologies, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.